Sunesis Pharmaceuticals to Host Conference Call on November 12th to Discuss Third Quarter 2019 Financial Results and Recent H...
October 29 2019 - 7:00AM
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that
it will host a conference call on Tuesday, November 12th, 2019 at
4:30 p.m. Eastern Time to discuss corporate updates and financial
results for the third quarter ended September 30, 2019.
The call can be accessed by dialing (844) 296-7720
(U.S. and Canada) or (574) 990-1148 (International) and entering
passcode 4059849.
To access the live audio webcast, or the subsequent
archived recording, visit the "Investors and Media - Calendar of
Events" section of the Sunesis website at
http://ir.sunesis.com/events-and-presentations/upcoming-events. The
webcast will be recorded and available for replay on the company's
website for two weeks.
About Sunesis
Pharmaceuticals
Sunesis is a biopharmaceutical company
developing novel targeted inhibitors for the treatment of
hematologic and solid cancers. Sunesis has built an experienced
drug development organization committed to improving the lives of
people with cancer. The Company is focused on advancing its novel
kinase inhibitor pipeline, with an emphasis on its oral
non-covalent BTK inhibitor vecabrutinib. Vecabrutinib is currently
being evaluated in a Phase 1b/2 study in adults with chronic
lymphocytic leukemia and other B-cell malignancies that have
progressed after prior therapies.
For additional information on Sunesis, please
visit www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis
Pharmaceuticals, Inc.
This press release contains forward-looking
statements, including statements related to the continued
development of vecabrutinib (SNS-062). Words such as "to," “will,”
“can be,” “look forward,” and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are based upon Sunesis' current expectations.
Forward-looking statements involve risks and uncertainties.
Sunesis' actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of these risks and uncertainties. These and
other risk factors are discussed under "Risk Factors" in Sunesis'
Quarterly Report on Form 10-Q for the quarter ended June 30,
2019 and Sunesis' other filings with the Securities and
Exchange Commission. Sunesis expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in Sunesis' expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements
are based.
Investor and Media Inquiries: |
|
|
|
Maeve Conneighton |
|
|
Willie Quinn |
Argot Partners |
|
|
Sunesis Pharmaceuticals Inc. |
212-600-1902 |
|
|
650-266-3716 |
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Apr 2023 to Apr 2024